市場調査レポート

商品コード

1451627

細胞治療市場レポート：細胞タイプ、治療タイプ、治療領域、エンドユーザー、地域別、2024-2032

Cell Therapy Market Report by Cell Type, Therapy Type, Therapeutic Area, End User, and Region 2024-2032

出版日: 2024年03月02日
発行: IMARC
ページ情報: 英文 139 Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF & Excel (Single User License)

USD 2,999 446,551円

レポートPDFおよびExcelを1名のみがご利用頂けるライセンスです。PDFおよびExcelの印刷は一度のみ可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (5 User License)

USD 3,999 595,451円

レポートPDFおよびExcelを同一企業内の5名様までがご利用頂けるライセンスです。PDFおよびExcelの印刷は可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Corporate License)

USD 4,999 744,351円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等の編集は可能ですが、事前にIMARC Services Private Limited社の許可が必要です。PDFおよびExcelの印刷回数に制限はありません。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=148.90円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の細胞治療市場規模は2023年に135億米ドルに達しました。今後、IMARC Groupは、2024年から2032年にかけて15.28%の成長率（CAGR）を示し、2032年までに505億米ドルに達すると予測しています。幹細胞研究の進展、世界のヘルスケアインフラの整備、患者意識の高まり、政府支援の拡大、保険適用範囲の拡大などが市場を後押しする要因のひとつです。

細胞治療（CT）には、組織や細胞の損傷に対処するためのヒト細胞の移植が含まれ、様々な病状に解決策を提供します。この包括的なアプローチには、造血幹細胞（HSC）、骨格筋幹細胞、間葉系幹細胞、リンパ球、樹状細胞、膵島細胞など、さまざまな種類の細胞が組み込まれています。その用途は、がん治療のための免疫系強化にとどまらず、自己免疫疾患や感染症、泌尿器系疾患、関節軟骨損傷、脊髄損傷、免疫系の弱体化、神経疾患などの管理にも及ぶ。再生医薬品の製造において極めて重要な役割を果たしており、組織や臓器の修復、加齢や病気、怪我によって影響を受けた機能の回復を目的とした新しい治療法の開発と実施を可能にしています。

世界市場は、バイオテクノロジーの急速な進歩が大きな原動力となっています。これに伴い、研究開発活動の活発化が市場に大きく貢献しています。さらに、政府や民間投資家からの資金提供の増加は、研究と商業化を促進しています。これとは別に、臨床試験活動の拡大が細胞治療の有効性と安全性を検証し、市場を活性化しています。さらに、慢性疾患や変性疾患の罹患率の増加は、先進的な治療オプションを必要とし、市場を促進しています。高齢化社会では、加齢に関連した疾患に対する再生療法が必要とされ、市場を強化しています。また、個々の患者に合わせた個別化細胞治療が普及しつつあり、市場の成長を促進しています。規制機関は細胞治療の承認に明確な道筋を示し、市場の明るい見通しを生み出しています。競合は細胞治療製品の革新と多様化を促進します。加えて、希少疾患の蔓延が市場を後押ししています。

細胞治療市場の動向と促進要因：

がんや心臓異常など様々な疾患の有病率の増加

様々な疾患、特にがんや心臓異常の有病率の増加が市場に好影響を与えています。高齢化、ライフスタイルの変化、環境の影響などの要因により、これらの疾患の世界の負担は着実に増加しています。細胞治療は、特殊な細胞の再生・修復特性を利用することで、これらの疾患の治療や治癒の可能性に大きな期待が寄せられています。がんに対しては、CAR-T細胞治療に代表される細胞ベースの免疫療法が、がん細胞を標的として排除することに顕著な成功を示しています。心臓異常の場合、幹細胞を用いた治療法は、損傷した心臓組織を修復し、心機能を改善することを目的としています。これらの広く蔓延し、生命を脅かす疾患に対する効果的な治療法の緊急の必要性が、細胞治療アプローチに対する広範な研究開発、投資を後押ししています。

細胞ベースの臨床研究の増加

細胞ベースの治療法に関する臨床試験の増加が市場の成長を後押ししています。臨床試験は、こうした革新的な治療法の安全性と有効性を検証する上で基本的な役割を果たしています。臨床研究が増加するにつれ、がん、自己免疫疾患、変性疾患などの様々な病状に対処するための新規治療に対する需要も増加しています。製薬会社、学術機関、バイオテクノロジー企業は、細胞ベースの治療法を市場に投入するため、これらの臨床試験を積極的に実施しています。これらの試験から得られた豊富なデータは、細胞治療の治療可能性を示すだけでなく、治療プロトコルの改良や最適な患者集団の特定にも役立っています。さらに、米国のFDAのような規制機関は、細胞ベースの治療法の承認プロセスを積極的に支援し、迅速化することで、臨床試験の開始をさらに後押ししています。その結果、臨床試験の増加は細胞治療の進歩を促し、イノベーションを促進し、必要とする患者へのアクセスを拡大します。このことは、臨床研究が市場を牽引する重要な役割を担っていることを裏付けています。

世界のヘルスケア産業の拡大

世界的に拡大するヘルスケア産業は、市場に数多くの機会を提供しています。人口が増加し、高齢化が進み、慢性疾患の負担が増大するにつれて、先進医療に対する需要が著しく高まっています。ヘルスケア分野の拡大には、細胞ベースの治療のような最先端の治療法の開発も含まれます。世界中のヘルスケア・システムは、がんや心血管疾患から神経疾患や自己免疫疾患に至るまで、幅広い病状に対処する細胞治療の可能性を認識しています。この認識は、再生医療や細胞治療への投資、調査、臨床試験の増加に結びついています。さらに、新興国ではヘルスケアのインフラが整備され、細胞治療を含む先進医療へのアクセスが向上しています。このようなヘルスケアサービスの世界の拡大は、細胞ベースの治療を受ける潜在的な患者層を拡大し、市場の成長を促進します。

北米
- 米国
  - 市場動向
  - 市場予測
- カナダ
  - 市場動向
  - 市場予測
アジア太平洋
- 中国
  - 市場動向
  - 市場予測
- 日本
  - 市場動向
  - 市場予測
- インド
  - 市場動向
  - 市場予測
- 韓国
  - 市場動向
  - 市場予測
- オーストラリア
  - 市場動向
  - 市場予測
- インドネシア
  - 市場動向
  - 市場予測
- その他
  - 市場動向
  - 市場予測
欧州
- ドイツ
  - 市場動向
  - 市場予測
- フランス
  - 市場動向
  - 市場予測
- 英国
  - 市場動向
  - 市場予測
- イタリア
  - 市場動向
  - 市場予測
- スペイン
  - 市場動向
  - 市場予測
- ロシア
  - 市場動向
  - 市場予測
- その他
  - 市場動向
  - 市場予測
ラテンアメリカ
- ブラジル
  - 市場動向
  - 市場予測
- メキシコ
  - 市場動向
  - 市場予測
- その他
  - 市場動向
  - 市場予測
中東・アフリカ地域
- 市場動向
- 市場内訳：国別
- 市場予測

第11章 SWOT分析

概要
強み
弱み
機会
脅威

第12章バリューチェーン分析

第13章ポーターのファイブフォース分析

概要
買い手の交渉力
供給企業の交渉力
競合の程度
新規参入業者の脅威
代替品の脅威

第14章価格分析

第15章競合情勢

市場構造
主要企業
主要企業のプロファイル
- AlloSource
- Anterogen Co. Ltd.
- Cells for Cells
- Holostem Terapie Avanzate S.r.l.
- JCR Pharmaceuticals
- Kolon TissueGene Inc.
- MEDIPOST
- Mesoblast Limited
- NuVasive
- Stemedica Cell Technologies Inc.
- Stempeutics Research Pvt. Ltd
- Vericel Corporation

図表

List of Figures

Figure 1: Global: Cell Therapy Market: Major Drivers and Challenges
Figure 2: Global: Cell Therapy Market: Sales Value (in Billion US$), 2018-2023
Figure 3: Global: Cell Therapy Market Forecast: Sales Value (in Billion US$), 2024-2032
Figure 4: Global: Cell Therapy Market: Breakup by Cell Type (in %), 2023
Figure 5: Global: Cell Therapy Market: Breakup by Therapy Type (in %), 2023
Figure 6: Global: Cell Therapy Market: Breakup by Therapeutic Area (in %), 2023
Figure 7: Global: Cell Therapy Market: Breakup by End User (in %), 2023
Figure 8: Global: Cell Therapy Market: Breakup by Region (in %), 2023
Figure 9: Global: Cell Therapy (Stem Cell) Market: Sales Value (in Million US$), 2018 & 2023
Figure 10: Global: Cell Therapy (Stem Cell) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 11: Global: Cell Therapy (Non-stem Cell) Market: Sales Value (in Million US$), 2018 & 2023
Figure 12: Global: Cell Therapy (Non-stem Cell) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 13: Global: Cell Therapy (Autologous) Market: Sales Value (in Million US$), 2018 & 2023
Figure 14: Global: Cell Therapy (Autologous) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 15: Global: Cell Therapy (Allogeneic) Market: Sales Value (in Million US$), 2018 & 2023
Figure 16: Global: Cell Therapy (Allogeneic) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 17: Global: Cell Therapy (Malignancies) Market: Sales Value (in Million US$), 2018 & 2023
Figure 18: Global: Cell Therapy (Malignancies) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 19: Global: Cell Therapy (Musculoskeletal Disorders) Market: Sales Value (in Million US$), 2018 & 2023
Figure 20: Global: Cell Therapy (Musculoskeletal Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 21: Global: Cell Therapy (Autoimmune Disorders) Market: Sales Value (in Million US$), 2018 & 2023
Figure 22: Global: Cell Therapy (Autoimmune Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 23: Global: Cell Therapy (Dermatology) Market: Sales Value (in Million US$), 2018 & 2023
Figure 24: Global: Cell Therapy (Dermatology) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 25: Global: Cell Therapy (Other Therapeutic Areas) Market: Sales Value (in Million US$), 2018 & 2023
Figure 26: Global: Cell Therapy (Other Therapeutic Areas) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 27: Global: Cell Therapy (Hospitals and Clinics) Market: Sales Value (in Million US$), 2018 & 2023
Figure 28: Global: Cell Therapy (Hospitals and Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 29: Global: Cell Therapy (Academic and Research Institutes) Market: Sales Value (in Million US$), 2018 & 2023
Figure 30: Global: Cell Therapy (Academic and Research Institutes) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 31: North America: Cell Therapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 32: North America: Cell Therapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 33: United States: Cell Therapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 34: United States: Cell Therapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 35: Canada: Cell Therapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 36: Canada: Cell Therapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 37: Asia-Pacific: Cell Therapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 38: Asia-Pacific: Cell Therapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 39: China: Cell Therapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 40: China: Cell Therapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 41: Japan: Cell Therapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 42: Japan: Cell Therapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 43: India: Cell Therapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 44: India: Cell Therapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 45: South Korea: Cell Therapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 46: South Korea: Cell Therapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 47: Australia: Cell Therapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 48: Australia: Cell Therapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 49: Indonesia: Cell Therapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 50: Indonesia: Cell Therapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 51: Others: Cell Therapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 52: Others: Cell Therapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 53: Europe: Cell Therapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 54: Europe: Cell Therapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 55: Germany: Cell Therapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 56: Germany: Cell Therapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 57: France: Cell Therapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 58: France: Cell Therapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 59: United Kingdom: Cell Therapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 60: United Kingdom: Cell Therapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 61: Italy: Cell Therapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 62: Italy: Cell Therapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 63: Spain: Cell Therapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 64: Spain: Cell Therapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 65: Russia: Cell Therapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 66: Russia: Cell Therapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 67: Others: Cell Therapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 68: Others: Cell Therapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 69: Latin America: Cell Therapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 70: Latin America: Cell Therapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 71: Brazil: Cell Therapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 72: Brazil: Cell Therapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 73: Mexico: Cell Therapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 74: Mexico: Cell Therapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 75: Others: Cell Therapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 76: Others: Cell Therapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 77: Middle East and Africa: Cell Therapy Market: Sales Value (in Million US$), 2018 & 2023
Figure 78: Middle East and Africa: Cell Therapy Market: Breakup by Country (in %), 2023
Figure 79: Middle East and Africa: Cell Therapy Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 80: Global: Cell Therapy Industry: SWOT Analysis
Figure 81: Global: Cell Therapy Industry: Value Chain Analysis
Figure 82: Global: Cell Therapy Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Cell Therapy Market: Key Industry Highlights, 2023 & 2032
Table 2: Global: Cell Therapy Market Forecast: Breakup by Cell Type (in Million US$), 2024-2032
Table 3: Global: Cell Therapy Market Forecast: Breakup by Therapy Type (in Million US$), 2024-2032
Table 4: Global: Cell Therapy Market Forecast: Breakup by Therapeutic Area (in Million US$), 2024-2032
Table 5: Global: Cell Therapy Market Forecast: Breakup by End User (in Million US$), 2024-2032
Table 6: Global: Cell Therapy Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 7: Global: Cell Therapy Market: Competitive Structure
Table 8: Global: Cell Therapy Market: Key Players

Product Code: SR112024A6231

The global cell therapy market size reached US$ 13.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 50.5 Billion by 2032, exhibiting a growth rate (CAGR) of 15.28% during 2024-2032. The increasing advances in stem cell research, the rising healthcare infrastructure across the globe, the growing patient awareness, the escalating government support, and the expanding insurance coverage are some of the factors propelling the market.

Cell therapy (CT) involves the transplantation of human cells to address tissue and cell damage, providing solutions for various medical conditions. This encompassing approach incorporates different cell types, including hematopoietic stem cells (HSC), skeletal muscle and mesenchymal stem cells, lymphocytes, dendritic cells, and pancreatic islet cells. Its applications extend beyond immune system enhancement for cancer treatment to encompass the management of autoimmune and infectious diseases, urinary issues, joint cartilage damage, spinal cord injuries, weakened immune systems, and neurological disorders. It plays a pivotal role in manufacturing regenerative medicines, enabling the development and implementation of novel treatments aimed at tissue and organ restoration and the recovery of functions impacted by aging, diseases, or injuries.

The global market is majorly driven by the rapid advancements in biotechnology. In line with this, the increasing research and development activities are significantly contributing to the market. Furthermore, the rising funding from governments and private investors fuels research and commercialization. Apart from this, the expanding clinical trial activities validate the efficacy and safety of cell therapies, catalyzing the market. Moreover, the growing incidence of chronic and degenerative diseases necessitates advanced treatment options, propelling the market. An aging demographic requires regenerative therapies for age-related conditions, bolstering the market. Besides, personalized cell therapies tailored to individual patients are gaining traction, fostering market growth. Regulatory bodies provide clearer pathways for cell therapy approvals, creating a positive outlook for the market. Competition drives innovation and diversification of cell therapy products. Additionally, the escalating prevalence of rare diseases is providing a boost to the market.

Cell Therapy Market Trends/Drivers:

Increasing prevalence of various diseases, such as cancer and cardiac abnormalities

The increasing prevalence of various diseases, particularly cancer and cardiac abnormalities, is favorably impacting the market. The global burden of these diseases has steadily risen due to factors like aging populations, lifestyle changes, and environmental influences. Cell therapy holds immense promise in treating and potentially curing these conditions by utilizing specialized cells' regenerative and reparative properties. For cancer, cell-based immunotherapies, such as CAR-T cell therapy, have shown remarkable success in targeting and eliminating cancer cells. In the case of cardiac abnormalities, stem cell-based therapies aim to repair damaged heart tissue and improve cardiac function. The urgent need for effective treatments for these widespread and life-threatening diseases propels extensive research, development, and investment in cell therapy approaches.

Rising number of clinical studies for cell-based therapies

The rising number of clinical studies for cell-based therapies is fueling the market growth. Clinical trials play a fundamental role in validating the safety and efficacy of these innovative treatments. As clinical studies grow, the demand for novel therapies to address various medical conditions such as cancer, autoimmune diseases, and degenerative disorders grows. Pharmaceutical companies, academic institutions, and biotechnology firms are actively conducting these trials to bring cell-based therapies to the market. The wealth of data generated from these studies demonstrates the therapeutic potential of cell therapies but also aids in refining treatment protocols and identifying the most suitable patient populations. Moreover, regulatory agencies like the FDA in the United States actively support and expedite the approval process for cell-based therapies, further incentivizing the initiation of clinical trials. As a result, the increasing number of clinical studies catalyzes advancing cell therapies, fostering innovation and expanding their accessibility to needy patients. This factor underscores the significant role clinical research plays in propelling the market.

Expanding healthcare industry worldwide

The expanding healthcare industry worldwide is offering numerous opportunities for the market. As populations grow, age, and face an increasing burden of chronic diseases, the demand for advanced medical treatments rises significantly. The healthcare sector's expansion includes the development of cutting-edge therapies like cell-based treatments. Healthcare systems across the globe are recognizing the potential of cell therapy in addressing a wide range of medical conditions, from cancer and cardiovascular diseases to neurological disorders and autoimmune conditions. This recognition translates into increased investment, research, and clinical trials in regenerative medicine and cell therapy. Moreover, as healthcare infrastructure improves in emerging economies, there is greater accessibility to advanced medical treatments, including cell therapies. This global expansion of healthcare services broadens the potential patient pool for cell-based treatments, driving market growth.

Cell Therapy Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global cell therapy market report, along with forecasts at the global, regional and country levels for 2024-2032. Our report has categorized the market based on cell type, therapy type, therapeutic area, and end user.

Breakup by Cell Type:

Stem Cell

Bone Marrow

Blood

Umbilical Cord-Derived

Adipose-Derived Stem Cell

Others

Non-stem Cell

Stem cell dominates the market

The report has provided a detailed breakup and analysis of the market based on the cell type. This includes stem cell (bone marrow, blood, umbilical cord-derived, adipose-derived stem cell, and others) and non-stem cell. According to the report, stem cell represented the largest segment.

Stem cells, with their remarkable regenerative potential and ability to differentiate into various cell types, have garnered significant attention in the medical field. These versatile cells are instrumental in treating a wide spectrum of diseases, including degenerative disorders, neurological conditions, and hematological malignancies. The increasing prevalence of age-related diseases and chronic conditions has intensified the demand for effective stem cell-based treatments. Moreover, ongoing research and clinical trials continue to unveil new therapeutic possibilities for stem cells, further fueling market growth. Pharmaceutical and biotechnology firms heavily invest in stem cell research, focusing on developing innovative therapies.

Furthermore, regulatory agencies are recognizing the importance of stem cell therapies, streamlining approval processes, and safety standards. This facilitates the commercialization of stem cell-based treatments, making them more accessible to patients worldwide. The stem cell segment is a powerful driver of growth in the cell therapy market, promising revolutionary solutions for numerous medical challenges.

Breakup by Therapy Type:

Autologous

Allogeneic

Autologous dominates the market

The report has provided a detailed breakup and analysis of the market based on the therapy type. This includes autologous and allogeneic. According to the report, autologous represented the largest segment.

Autologous therapies involve the extraction, manipulation, and reinfusion of a patient's cells, minimizing the risk of rejection and adverse reactions. This personalized approach has gained prominence in treating various conditions, including cancer, autoimmune diseases, and degenerative disorders. The increasing demand for therapies with higher safety profiles and reduced immune complications has fueled the adoption of autologous cell therapies. These treatments harness the regenerative potential of a patient's cells, addressing unmet medical needs while minimizing the risks associated with allogeneic treatments, where cells are sourced from donors.

Furthermore, advancements in cell processing techniques, such as CAR-T cell therapies for cancer treatment, showcase the remarkable potential of autologous therapies. Regulatory agencies are also streamlining approval pathways for these personalized treatments, expediting their availability to a wider patient population. As a result, the autologous therapy segment is a pivotal driver of growth in the cell therapy market, offering innovative and patient-centric solutions for various medical conditions.

Breakup by Therapeutic Area:

Malignancies

Musculoskeletal Disorders

Autoimmune Disorders

Dermatology

Others

Malignancies dominate the market

The report has provided a detailed breakup and analysis of the market based on the therapeutic area. This includes malignancies, musculoskeletal disorders, autoimmune disorders, dermatology, and others. According to the report, malignancies represented the largest segment.

Malignancies, including various types of cancer, present one of the most challenging healthcare concerns globally. Cell therapies, such as CAR-T, have emerged as groundbreaking treatments for these conditions. The growing incidence of cancer and the increasing demand for more effective and targeted therapies have propelled the development and adoption of cell-based treatments. These therapies harness the patient's immune system or engineered cells to target and eliminate cancer cells. Their remarkable success in clinical trials and real-world applications underscores their potential to transform cancer treatment.

Moreover, regulatory agencies are expediting approvals for cell therapies in oncology, streamlining their path to market. As a result, the malignancies-focused segment serves as a critical driver of growth in the cell therapy market, offering renewed hope to cancer patients and contributing to the evolution of cancer care.

Breakup by End User:

Hospitals and Clinics

Academic and Research Institutes

The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals and clinics, academic and research institutes.

Hospitals and clinics, with their advanced medical infrastructure and access to a broad patient base, are well-positioned to integrate cell therapy into their treatment protocols. They offer a range of cell-based treatments, including CAR-T cell therapy for cancer and stem cell therapies for various conditions, providing patients with advanced and personalized care options.

Furthermore, the collaboration between hospitals, clinics, and cell therapy companies fosters the expansion of clinical trials and the development of new therapies. As these healthcare facilities continue to recognize the potential of cell therapies in improving patient outcomes, their adoption and utilization of cell-based treatments contribute significantly to the market's overall growth.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance, accounting for the largest market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America boasts a robust and highly developed healthcare infrastructure, including advanced research institutions, hospitals, and clinical centers. These institutions actively engage in cell therapy research and clinical trials, accelerating the development and adoption of innovative cell-based treatments. The substantial investments in the biotechnology and pharmaceutical sectors facilitate the advancement of cell therapies. Pharmaceutical companies and biotech firms in the region actively contribute to cell therapy research and development, resulting in a steady stream of new therapies.

The regulatory agencies in North America, such as the FDA in the United States, play a crucial role in streamlining the approval process for cell therapies, ensuring they meet rigorous safety and efficacy standards. This regulatory support expedites the commercialization of these treatments. Moreover, the increasing prevalence of chronic diseases, including cancer, fuels the demand for effective and advanced therapies, making cell therapies an attractive option for patients and healthcare providers.

Competitive Landscape:

Top companies are strengthening the market through multifaceted strategies and contributions. These industry leaders prioritize extensive research and development, continuously pushing the boundaries of cell therapies by exploring novel cell types, delivery methods, and applications. They conduct rigorous clinical trials, substantiating the safety and efficacy of their therapies and obtaining regulatory approvals that enhance market credibility. Strategic collaborations and partnerships with research institutions, biotech firms, and healthcare organizations allow them to leverage combined expertise and resources. Top companies often expand their market reach globally, making cell therapies accessible to a broader patient base. Maintaining strict compliance with regulatory standards ensures that their therapies meet stringent safety and quality requirements, instilling confidence among healthcare professionals and patients. Additionally, initiatives to improve patient access, educational campaigns, and strategic acquisitions collectively reinforce their pivotal role in advancing cell therapies and fostering market growth.

The report has provided a comprehensive analysis of the competitive landscape in the cell therapy market. Detailed profiles of all major companies have also been provided.

AlloSource

Anterogen Co. Ltd.

Cells for Cells

Holostem Terapie Avanzate S.r.l.

JCR Pharmaceuticals

Kolon TissueGene Inc

MEDIPOST

Mesoblast Limited

NuVasive

Stemedica Cell Technologies Inc.

Stempeutics Research Pvt. Ltd

Vericel Corporation

Recent Developments:

In July 2023, AlloSource received FDA 510(K) clearance for AceConnex pre-sutured fascia for hip labral eeconstruction and augmentation.

In June 2020, Holostem Terapie Avanzate S.r.l signed a contract for the transfer of the business branch of Holoclar, an autologous stem-cell therapy for the treatment of patients with severe ocular surface burns, with Chiesi Farmaceutici, international research-focussed group (Chiesi Group).

In October 2022, MEDIPOST announced the launch of a Contract Development and Manufacturing Organization (CDMO) business for cell and gene therapy products in Korea.

Key Questions Answered in This Report

1. What was the size of the global cell therapy market in 2023?
2. What is the expected growth rate of the global cell therapy market during 2024-2032?
3. What has been the impact of COVID-19 on the global cell therapy market?
4. What are the key factors driving the global cell therapy market?
5. What is the breakup of the global cell therapy market based on the cell type?
6. What is the breakup of the global cell therapy market based on the therapy type?
7. What is the breakup of the global cell therapy market based on the therapeutic area?
8. What are the key regions in the global cell therapy market?
9. Who are the key players/companies in the global cell therapy market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Cell Therapy Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Cell Type

6.1 Stem Cell
- 6.1.1 Market Trends
- 6.1.2 Key Segments
  - 6.1.2.1 Bone Marrow
  - 6.1.2.2 Blood
  - 6.1.2.3 Umbilical Cord-Derived
  - 6.1.2.4 Adipose-Derived Stem Cell
  - 6.1.2.5 Others
- 6.1.3 Market Forecast
6.2 Non-stem Cell
- 6.2.1 Market Trends
- 6.2.2 Market Forecast

7 Market Breakup by Therapy Type

7.1 Autologous
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Allogeneic
- 7.2.1 Market Trends
- 7.2.2 Market Forecast

8 Market Breakup by Therapeutic Area

8.1 Malignancies
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Musculoskeletal Disorders
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Autoimmune Disorders
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
8.4 Dermatology
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
8.5 Others
- 8.5.1 Market Trends
- 8.5.2 Market Forecast

9 Market Breakup by End User

9.1 Hospitals and Clinics
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
9.2 Academic and Research Institutes
- 9.2.1 Market Trends
- 9.2.2 Market Forecast

10 Market Breakup by Region

10.1 North America
- 10.1.1 United States
  - 10.1.1.1 Market Trends
  - 10.1.1.2 Market Forecast
- 10.1.2 Canada
  - 10.1.2.1 Market Trends
  - 10.1.2.2 Market Forecast
10.2 Asia-Pacific
- 10.2.1 China
  - 10.2.1.1 Market Trends
  - 10.2.1.2 Market Forecast
- 10.2.2 Japan
  - 10.2.2.1 Market Trends
  - 10.2.2.2 Market Forecast
- 10.2.3 India
  - 10.2.3.1 Market Trends
  - 10.2.3.2 Market Forecast
- 10.2.4 South Korea
  - 10.2.4.1 Market Trends
  - 10.2.4.2 Market Forecast
- 10.2.5 Australia
  - 10.2.5.1 Market Trends
  - 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
  - 10.2.6.1 Market Trends
  - 10.2.6.2 Market Forecast
- 10.2.7 Others
  - 10.2.7.1 Market Trends
  - 10.2.7.2 Market Forecast
10.3 Europe
- 10.3.1 Germany
  - 10.3.1.1 Market Trends
  - 10.3.1.2 Market Forecast
- 10.3.2 France
  - 10.3.2.1 Market Trends
  - 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
  - 10.3.3.1 Market Trends
  - 10.3.3.2 Market Forecast
- 10.3.4 Italy
  - 10.3.4.1 Market Trends
  - 10.3.4.2 Market Forecast
- 10.3.5 Spain
  - 10.3.5.1 Market Trends
  - 10.3.5.2 Market Forecast
- 10.3.6 Russia
  - 10.3.6.1 Market Trends
  - 10.3.6.2 Market Forecast
- 10.3.7 Others
  - 10.3.7.1 Market Trends
  - 10.3.7.2 Market Forecast
10.4 Latin America
- 10.4.1 Brazil
  - 10.4.1.1 Market Trends
  - 10.4.1.2 Market Forecast
- 10.4.2 Mexico
  - 10.4.2.1 Market Trends
  - 10.4.2.2 Market Forecast
- 10.4.3 Others
  - 10.4.3.1 Market Trends
  - 10.4.3.2 Market Forecast
10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast

11 SWOT Analysis

11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
- 15.3.1 AlloSource
  - 15.3.1.1 Company Overview
  - 15.3.1.2 Product Portfolio
  - 15.3.1.3 SWOT Analysis
- 15.3.2 Anterogen Co. Ltd.
  - 15.3.2.1 Company Overview
  - 15.3.2.2 Product Portfolio
  - 15.3.2.3 Financials
- 15.3.3 Cells for Cells
  - 15.3.3.1 Company Overview
  - 15.3.3.2 Product Portfolio
- 15.3.4 Holostem Terapie Avanzate S.r.l.
  - 15.3.4.1 Company Overview
  - 15.3.4.2 Product Portfolio
- 15.3.5 JCR Pharmaceuticals
  - 15.3.5.1 Company Overview
  - 15.3.5.2 Product Portfolio
  - 15.3.5.3 Financials
  - 15.3.5.4 SWOT Analysis
- 15.3.6 Kolon TissueGene Inc.
  - 15.3.6.1 Company Overview
  - 15.3.6.2 Product Portfolio
  - 15.3.6.3 Financials
- 15.3.7 MEDIPOST
  - 15.3.7.1 Company Overview
  - 15.3.7.2 Product Portfolio
  - 15.3.7.3 Financials
- 15.3.8 Mesoblast Limited
  - 15.3.8.1 Company Overview
  - 15.3.8.2 Product Portfolio
  - 15.3.8.3 Financials
- 15.3.9 NuVasive
  - 15.3.9.1 Company Overview
  - 15.3.9.2 Product Portfolio
  - 15.3.9.3 Financials
  - 15.3.9.4 SWOT Analysis
- 15.3.10 Stemedica Cell Technologies Inc.
  - 15.3.10.1 Company Overview
  - 15.3.10.2 Product Portfolio
- 15.3.11 Stempeutics Research Pvt. Ltd
  - 15.3.11.1 Company Overview
  - 15.3.11.2 Product Portfolio
- 15.3.12 Vericel Corporation
  - 15.3.12.1 Company Overview
  - 15.3.12.2 Product Portfolio
  - 15.3.12.3 Financials
  - 15.3.12.4 SWOT Analysis

細胞治療市場レポート：細胞タイプ、治療タイプ、治療領域、エンドユーザー、地域別、2024-2032

Cell Therapy Market Report by Cell Type, Therapy Type, Therapeutic Area, End User, and Region 2024-2032

細胞治療市場の動向と促進要因：

目次

第1章 序文

第2章 調査範囲と調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 細胞治療の世界市場

第6章 市場内訳：細胞タイプ別

第7章 市場内訳：治療タイプ別

第8章 市場内訳：治療領域別

第9章 市場内訳：エンドユーザー別

第10章 市場内訳：地域別

第11章 SWOT分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

第14章 価格分析

第15章 競合情勢

List of Figures

List of Tables

Cell Therapy Market Trends/Drivers:

Cell Therapy Industry Segmentation:

Breakup by Cell Type:

Breakup by Therapy Type:

Breakup by Therapeutic Area:

Breakup by End User:

Breakup by Region:

Competitive Landscape:

Recent Developments:

Key Questions Answered in This Report

Table of Contents

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global Cell Therapy Market

6 Market Breakup by Cell Type

7 Market Breakup by Therapy Type

8 Market Breakup by Therapeutic Area

9 Market Breakup by End User

10 Market Breakup by Region

11 SWOT Analysis

12 Value Chain Analysis

13 Porters Five Forces Analysis

14 Price Analysis

15 Competitive Landscape

第1章序文

第2章調査範囲と調査手法

第3章エグゼクティブサマリー

第4章イントロダクション

第5章細胞治療の世界市場

第6章市場内訳：細胞タイプ別

第7章市場内訳：治療タイプ別

第8章市場内訳：治療領域別

第9章市場内訳：エンドユーザー別

第10章市場内訳：地域別

第12章バリューチェーン分析

第13章ポーターのファイブフォース分析

第14章価格分析

第15章競合情勢